Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: GILD

Gilead Sciences, Inc.

Healthcare | Drug Manufacturers - General

Market prices for GILD are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-2.66

Gilead Sciences, Inc. (NASDAQ: GILD) is a drug manufacturer. Figures from SEC EDGAR; updated 2026-10-18 19:23 UTC.

What Gilead Sciences, Inc. does

Gilead Sciences is a biopharmaceutical company that discovers, develops, and delivers medicines to treat diseases including HIV, viral hepatitis, COVID-19, and cancer. The company operates in more than 35 countries with headquarters in Foster City, California. In 2025, Gilead's commercial portfolio included more than 25 therapies across therapeutic areas such as virology and oncology, with products like Biktarvy and Descovy for HIV treatment, Epclusa for hepatitis C, and Tecartus and Yescarta for certain cancers.

Summarized from Gilead Sciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-2.66
Debt/equity2.42

Revenue, margins & earnings

FY2021 Net income: $6.22BFY2021 Taxes & interest: $3.69BFY2021 Operating costs: $17.4B$27.3BFY2021FY2022 Net income: $4.59BFY2022 Taxes & interest: $2.74BFY2022 Operating costs: $20.0B$27.3BFY2022FY2023 Net income: $5.67BFY2023 Taxes & interest: $1.94BFY2023 Operating costs: $19.5B$27.1BFY2023FY2024 Net income: $480MFY2024 Taxes & interest: $1.18BFY2024 Operating costs: $27.1B$28.8BFY2024FY2025 Net income: $8.51BFY2025 Taxes & interest: $1.51BFY2025 Operating costs: $19.4B$29.4BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-16
  • 2026-10-16Chief Comm & Corp Aff OfficerSale-3,000$468.7K
  • 2026-10-16Chief Financial OfficerSale-3,000$468.7K
  • 2026-10-02Chairman & CEOSale-12,000$1.77M
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Gilead Sciences, Inc. do?

Gilead Sciences is a biopharmaceutical company that discovers, develops, and delivers medicines to treat diseases including HIV, viral hepatitis, COVID-19, and cancer.

When did GILD last file with the SEC?

Gilead Sciences, Inc.'s most recent SEC filing on record is a SCHEDULE 13D/A filed 2026-08-07. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-18 19:23 UTC. This page is also available as JSON at /api/data?ticker=GILD and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for GILD and 5,000+ tickers.

Create a free account — keep GILD
For your agent
GET /api/data?ticker=GILD

This page as JSON via rel="alternate" · REST API docs · MCP server (62 tools) · llms.txt